A new real-world study shows that myelofibrosis (MF) is a complex disease that affects everyone differently, and treatment should be tailored to each patient’s unique situation. Researchers found that factors like genetics (including JAK2, CALR, or MPL mutations), disease subtype, age, symptoms, and blood counts all influence how MF progresses and how patients respond to therapies.
For example, patients who received ruxolitinib as their first treatment often stayed on therapy longer compared to those who received hydroxyurea, especially if they had the JAK2 V617F mutation or developed MF after polycythemia vera. However, this didn’t lead to a significant difference in overall survival across different treatment groups.
These findings reinforce that managing MF is not “one size fits all.” While certain medications may work better for some people—especially based on genetic mutations or MF subtype—treatment needs to be personalized. Working closely with your care team to consider all aspects of your disease, discuss genetic testing, and review your response to therapy over time can help you get the most out of your treatment plan.
Reference
Flaherty D. Abstract MPN-1046, SOHO 2025, 2-7 September 2025.
